SEC Form 4 · accession 0001415889-18-001750
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew A Roberts
Officer — CHIEF SCIENTIFIC OFFICER
Period of report
Dec 10, 2018
Accepted (ET)
Dec 11, 2018 · 7:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $2.85 | Dec 10, 2018 | A | 350,000 | A | — | Dec 10, 2028 | Common Stock | 350,000 | 350,000 | D |
Explanation of responses
- F1One-third of the shares subject to the option vest on December 10, 2019, and the remaining shares subject to the option vest in a series of 24 equal monthly installments thereafter on each such vesting date.